Stifel raised the firm’s price target on Cytokinetics (CYTK) to $108 from $98 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Maxwell Skor Lifts Cytokinetics Price Target to $103 and Reiterates Buy on Strong Phase 3 ACACIA-HCM Results for Aficamten
- Cytokinetics Earnings Call Highlights Launch, Trial Wins
- Cytokinetics Highlights MYQORZO Progress and Cardiology Pipeline
- Analyst Maintains Buy Rating and $136 Price Target on Aficamten Following Strong Phase 3 ACACIA-HCM Results
- Morning News Wrap-Up, 5/5/26: Today’s Biggest Stock Market Stories!